Step-By-Step Look At MACI Procedure & Rehabilitation  Skip to content

MACI offers 2 implant delivery options: minimally invasive arthroscopy and mini-arthrotomy

Watch these videos to learn more about delivering MACI

A step-by-step guide to MACI implantation

MACI instrumentation is designed to support the delivery technique you choose.

MACI Arthro instrumentation is designed to create a reproducible technique for arthroscopic delivery while maintaining cell viability on the implant.3

With a range of Cannula, Cutter, and V-shuttle™ sizes to address accessible defects of the knee that are ≤4 cm2, MACI Arthro instruments are packaged separately to provide surgeons with the option to select the appropriate tools for each case. Ask your MACI Representative for more information.

Important note: MACI Arthro instrumentation is not available or appropriate for all MACI implantation procedures. The content presented here is for informational purposes only and does not constitute medical advice.

PDF icon MACI Arthro Instrument Symbols

MACI Open Instruments

MACI Open instrumentation is intended to assist with delivery of MACI via mini-arthrotomy. Ask your MACI Representative for more information.

Important note: MACI Open instrumentation is not available or appropriate for all MACI implantation procedures. The content presented here is for informational purposes only and does not constitute medical advice.

PDF icon MACI Open Instruments & Instructions for Use

MACI can be delivered to a wide range of knee cartilage defects via mini-arthrotomy and can now be delivered arthroscopically in patients with ≤4 cm2 accessible defects

Condyle

Condyle defect
Condyle debridement
Condyle MACI implantation

Trochlea

Trochlea defect
Trochlea debridement
Trochlea MACI implantation

Patella

Patella defect
Patella debridement
Patella MACI implantation
Question Icon

Questions about MACI?
Have materials sent to your practice.

#
Knee Icon

Find out how MACI can fit into your practice.

References: 1. Data On File (design history files 21-087-TR and 21-081-TR). 2. Saris D, Price A, Widuchowski W, et al; SUMMIT study group. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: two-year follow-up of a prospective randomized trial. Am J Sports Med. 2014;42(6):1384-1394. 3. Brittberg M, Recker D, Ilgenfritz J, Saris DBF; SUMMIT Extension Study Group. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: five-year follow-up of a prospective randomized trial. Am J Sports Med. 2018;46(6):1343-1351.

Indication and Important Safety Information

Important Safety Information

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.

Warnings and Precautions:
  • Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be possible.
  • Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
  • Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI implantation.
  • Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:
  • Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
  • The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

MACI® is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.

Safety and effectiveness of MACI in patients over the age of 55 years have not been established.